

Prior Authorization Request Form for Multiple Sclerosis Agent (Not for Tysabri or Zeposia)

FAX this completed form to (844) 205-3386

OR Mail requests to: Pharmacy Department | 5 River Park Place East, Suite 210 | Fresno, CA 93720 OR Prior authorization may be completed at https://www.covermymeds.com/main/prior-authorization-forms/

I. PROVIDER INFORMATION		II. MEMBER INFORMATION				
Prescriber Name:		Member Name:				
Prescriber Specialty:		Identification #:				
NPI:		Group #:				
Office Contact Name:		Date of Birth:				
Fax #:		Medication Allergies:				
Phone #:						
III. DRUG INFORMATION (One drug re	quest per form	m)				
Drug name and strength:	Dosage Interva	al (sig):		Qty. per Day:		
IV. REQUIRED DOCUMENTION (Detailed	ed medical rec	ord documenta	tion demor	nstrating evidence for each item		
must be submitted with prior authorized	ation request))				
Specify diagnosis & diagnosis code relevant to this request: Dx/Dx Code:						
□ Has relapsing form of MS (specify) → □ clinically isolated syndrome □ relapsing remitting disease □ active secondary progressive disease						
Has primary progressive MS						
Does the member have any contraindications	s to the prescribe	ed medication?	□ Yes □ No	Submit documentation.		
Requests for all non-preferred medication history of trial and failure of or contraindicat preferred Multiple Sclerosis agents? Refer to <u>drug-list</u> for a list of preferred and non-prefe Does not apply to non-preferred brands w equivalent generic is preferred or to non- therapeutically equivalent brand is prefer	ce to the om/preferred- is in this class. oeutically	□ Yes □ No	Submit documentation of previous trials/failures, contraindications, and/or intolerances or current use.			
□ If not prescribed by the following specialist, a neurologist or for Ampyra physical medicine and rehabilitation (PM&R) specialist, please indicate a specialist consulted:						
 Member has a current history (within past 90 days, or if greater than 90 days dosing interval is greater than 90 days) of using the prescribed the requested non-preferred multiple sclerosis agent, since: If requesting for daily quantity exceeding daily limit (Refer to https://www.dhs.pa.gov/providers/Pharmacy-services/Pages/Quantity-Limits-and-Daily-Dose-Limits.aspx), please provide supporting information: 						
SUBMIT MEDICAL RECORD INFORMATION FOR EACH APPLICABLE ITEM.						
REQUEST FOR AMPYRA (DALFAMPRIDINE						
Member has motor dysfunction on a continuous basis, impairing the ability to complete instrumental activities of daily living:						
REQUEST FOR MAVENCLAD (CLADRIBINE):						
Has documentation of recent lymphocyte count within recommended limits according to FDA-approved package labeling before initiating the first treatment course						

RENEWAL REQUESTS FOR ALL:

For Relapsing Form of MS, member has documented improvement or stabilizing of the multiple sclerosis disease
course:

For Primary Progressive MS, based on the prescriber's professional judgement, continues to benefit from the requested
agent

□ For Ampyra, member has improvement in motor function as evident by:_____

RENEWAL REQUEST FOR LEMTRADA (ALEMTUZUMAB):

Received the previous treatment course at least 12 months prior to the requested treatment course

RENEWAL REQUEST FOR MAVENCLAD (CLADRIBINE):

- □ Member meets all the following:
 - □ Has documentation of recent lymphocyte count within recommended limits according to FDA-approved package labeling before initiating the first treatment course
 - Has not exceeded the recommended total number of treatment courses according to FDA-approved package labeling

IV. ADDITIONAL RATIONALE FOR REQUEST / PERTINENT CLINICAL INFORMATION :

Appropriate clinical information to support the request on	Provider Signature:	Date:
the basis of medical necessity must be submitted.		

Pharmacy Department will respond via fax or phone within 24 hours.

Requests for prior authorization (PA) requests must include member name, ID#, and drug name. Please include lab reports with requests when appropriate (e.g., Culture and Sensitivity; Hemoglobin A1C; Serum Creatinine; CD4; Hematocrit; WBC, etc.)